Circle Pharma has appointed Anne Borgman as its new chief medical officer, the company announced January 9, 2026. Borgman brings extensive experience to the role, previously serving as chief medical officer at Sutro Biopharma.
Executive Shuffle: New Leadership at Circle Pharma
A key appointment signals growth for Circle Pharma as it welcomes a seasoned medical leader.
- Anne Borgman is the newly appointed chief medical officer at Circle Pharma.
- borgman previously held the same position at sutro Biopharma.
- the move highlights ongoing personnel changes within the pharmaceutical and biotech industries.
The pharmaceutical and biotech sectors continue to see a dynamic shift in leadership, with companies regularly announcing new hires and promotions. Circle Pharma’s decision to bring on Anne Borgman as chief medical officer is the latest example of this trend. Borgman’s prior experience as chief medical officer at Sutro Biopharma positions her well to guide Circle Pharma’s medical strategy.
Why the change? Circle Pharma seeks to bolster its medical leadership as it navigates an increasingly competitive pharmaceutical landscape. The company aims to accelerate its clinical development programs and strengthen its position in the market. Who is Anne Borgman? Borgman is a seasoned medical executive with a proven track record of success at Sutro Biopharma, where she led the medical strategy and clinical development efforts. Her expertise encompasses clinical trial design,regulatory submissions,and medical affairs. What will she do? As chief medical officer, Borgman will be responsible for overseeing all medical aspects of Circle Pharma’s drug development programs, from early-stage research to late-stage clinical trials and regulatory approval.She will also play a key role in shaping the company’s overall medical strategy.
The declaration comes amid a broader wave of job changes across the industry, with companies like gilead, Roche, Bristol Myers Squibb, and AstraZeneca also making notable personnel moves. The constant evolution of these roles underscores the competitive nature of the pharmaceutical and biotech world, where attracting and retaining top talent is paramount.
While the details surrounding Borgman’s specific responsibilities at Circle Pharma remain to be seen, her appointment signals the company’s commitment to strengthening its medical leadership team. The industry will be watching to see how her expertise shapes Circle Pharma’s future direction. How did it end? Borgman’s departure from Sutro Biopharma was amicable, allowing her to pursue this new possibility at Circle Pharma. Sutro Biopharma has initiated a search for her replacement, and the transition is expected to be seamless.
Related reading
